In 2022, the Gemigliptin Market worldwide was assessed at USD 1.66 billion. Analysts project it will expand to USD 2.65 billion by 2031, at a CAGR of 5.5% spanning 2023 to 2031.
At its core, Gemigliptin pertains to key industry insights & findings from the report:
Gemigliptin effectiveness in glycemic control, often in combination with other antidiabetic agents, has contributed to its widespread adoption. Stakeholders across the healthcare landscape are escalatingly turning to these solutions to meet contemporary demands.
The market's upward path is fueled by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gemigliptin Market Snapshot
Chapter 4. Global Gemigliptin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Drug Estimates & Trend Analysis
5.1. By Type of Drug, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Type of Drug:
5.2.1. Gemigliptin Monotherapy
5.2.2. Gemigliptin Combination Therapy
Chapter 6. Market Segmentation 2: By Dosage Form Estimates & Trend Analysis
6.1. By Dosage Form & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Dosage Form:
6.2.1. Gemigliptin Tablets
6.2.2. Gemigliptin Injectable
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Market Segmentation 4: By End-User Estimates & Trend Analysis
8.1. By End-User & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-User:
8.2.1. Hospitals
8.2.2. Clinics and Outpatient Facilities
8.2.3. Homecare Settings
Chapter 9. Market Segmentation 5: By Application Estimates & Trend Analysis
9.1. By Application & Market Share, 2020 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application:
9.2.1. Type 2 Diabetes
9.2.2. Prediabetes
Chapter 10. Market Segmentation 6: By Patient Demographics Estimates & Trend Analysis
10.1. By Patient Demographics & Market Share, 2020 & 2031
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Patient Demographics:
10.2.1. Adult Population
10.2.2. Geriatric Population
Chapter 11. Gemigliptin Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Type of Drug, 2019-2031
11.1.2. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Dosage Form, 2019-2031
11.1.3. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
11.1.4. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By End-User, 2019-2031
11.1.5. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
11.1.6. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts By Patient Demographics, 2019-2031
11.1.7. North America Gemigliptin Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
11.2. Europe
11.2.1. Europe Gemigliptin Market revenue (US$ Million) By Type of Drug, 2019-2031
11.2.2. Europe Gemigliptin Market revenue (US$ Million) By Dosage Form, 2019-2031
11.2.3. Europe Gemigliptin Market revenue (US$ Million) By Distribution Channel, 2019-2031
11.2.4. Europe Gemigliptin Market revenue (US$ Million) By End-User, 2019-2031
11.2.5. Europe Gemigliptin Market revenue (US$ Million) By Application, 2019-2031
11.2.6. Europe Gemigliptin Market revenue (US$ Million) By Patient Demographics, 2019-2031
11.2.7. Europe Gemigliptin Market revenue (US$ Million) by country, 2019-2031
11.3. Asia Pacific
11.3.1. Asia Pacific Gemigliptin Market revenue (US$ Million) By Type of Drug, 2019-2031
11.3.2. Asia Pacific Gemigliptin Market revenue (US$ Million) By Dosage Form, 2019-2031
11.3.3. Asia Pacific Gemigliptin Market revenue (US$ Million) By Distribution Channel, 2019-2031
11.3.4. Asia Pacific Gemigliptin Market revenue (US$ Million) By End-User, 2019-2031
11.3.5. Asia Pacific Gemigliptin Market revenue (US$ Million) By Application, 2019-2031
11.3.6. Asia Pacific Gemigliptin Market revenue (US$ Million) By Patient Demographics, 2019-2031
11.3.7. Asia Pacific Gemigliptin Market revenue (US$ Million) by country, 2019-2031
11.4. Latin America
11.4.1. Latin America Gemigliptin Market revenue (US$ Million) By Type of Drug, (US$ Million) 2019-2031
11.4.2. Latin America Gemigliptin Market revenue (US$ Million) By Dosage Form, (US$ Million) 2019-2031
11.4.3. Latin America Gemigliptin Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
11.4.4. Latin America Gemigliptin Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
11.4.5. Latin America Gemigliptin Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
11.4.6. Latin America Gemigliptin Market revenue (US$ Million) By Patient Demographics, (US$ Million) 2019-2031
11.4.7. Latin America Gemigliptin Market revenue (US$ Million) by country, 2019-2031
11.5. Middle East & Africa
11.5.1. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Type of Drug, (US$ Million) 2019-2031
11.5.2. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Dosage Form, (US$ Million) 2019-2031
11.5.3. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
11.5.4. Middle East & Africa Gemigliptin Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
11.5.5. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
11.5.6. Middle East & Africa Gemigliptin Market revenue (US$ Million) By Patient Demographics, (US$ Million) 2019-2031
11.5.7. Middle East & Africa Gemigliptin Market revenue (US$ Million) by country, 2019-2031
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. LG Chem,
12.2.2. Hanmi Pharmaceutical Co., Ltd.,
12.2.3. Boryung Pharmaceutical Co., Ltd.,
12.2.4. Novartis AG, EirGenix, Inc.,
12.2.5. Biocon Limited,
12.2.6. G.L. Pharma GmbH,
12.2.7. Daewoong Pharmaceutical Co., Ltd.,,
12.2.8. Sandoz International GmbH,
12.2.9. Boryung Pharmaceutical Co., Ltd.,
12.2.10. VHB Life Sciences Limited,
12.2.11. HanAll Biopharma,
12.2.12. Taiba Healthcare,
12.2.13. Huons Co., Ltd.,
12.2.14. Dong-A ST Co., Ltd.